Please assess the completion status of the following clinical trial:

Trial Title: Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed infantile, congenital, or pediatric fibrosarcoma~  * Initial biopsy or surgery performed within the past 35 days~* No evidence of distant metastases~* Available tissue for central review~PATIENT CHARACTERISTICS:~Age~* Under 2 at diagnosis~Performance status~* Zubrod Score (ECOG)~Life expectancy~* At least 8 weeks~Hematopoietic~* Absolute neutrophil count at least 1,000/mm\^3~* Platelet count at least 100,000/mm\^3\*~* Hemoglobin at least 10.0 g/dL\* NOTE: \*Transfusions allowed~Hepatic~* Total bilirubin no greater than 1.5 times upper limit of normal (ULN) (patients over 4 weeks of age)~  * Patients under 4 weeks of age with an indirect hyperbilirubinemia are eligible, provided the following criteria are met:~    * At least 2 bilirubin values at separate timepoints show a decrease in measurement~   * Direct bilirubin is no greater than 20% of the total bilirubin~* Direct bilirubin no greater than 1.5 times ULN~* Alanine Aminotransferase (ALT) less than 2.5 times ULN~Renal~* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min~PRIOR/CONCURRENT THERAPY:~Biologic therapy~* No concurrent sargramostim (GM-CSF)~Chemotherapy~* No prior chemotherapy~* No other concurrent anticancer chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior or concurrent radiotherapy except emergent radiotherapy for impending tracheal compression~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- Chemotherapy plus possible surgery (Type: EXPERIMENTAL): Comprised of patients with disease lesions that are initially unresectable, or resected but with resulting grossly positive margins. All patients receive vincristine sulfate, dactinomycin, and cyclophosphamide (VAC), and mercaptoethane sulfonate (MESNA). Depending on response, patients may receive ifosfamide and etoposide (IE). Filgrastim may also be given, as needed. In addition to Chemotherapy, patients may receive Conventional Surgery.~(See Interventions section for drug dosage and administration details.)
- Surgery only (Type: EXPERIMENTAL): Comprised of patients with initially resectable disease lesions. All patients undergo Conventional Surgery. Those with a result of clear or microscopically positive margins remain on study in this arm, for observation with no further intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).